LEPU MED.T.B. SP.GDR O.N. Asset Resilience Ratio

Latest as of March 2026: 1.37%

LEPU MED.T.B. SP.GDR O.N. asset resilience ratio. LEPU MED.T.B. SP.GDR O.N. (07Z0) has an Asset Resilience Ratio of 1.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read LEPU MED.T.B. SP.GDR O.N. debt and liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

€350.77 Million
≈ $410.09 Million USD Cash + Short-term Investments

Total Assets

€25.59 Billion
≈ $29.91 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of LEPU MED.T.B. SP.GDR O.N. (2022–2025)

Asset resilience ratio of LEPU MED.T.B. SP.GDR O.N. from 2022 to 2025. This chart shows how LEPU MED.T.B. SP.GDR O.N.'s Asset Resilience Ratio has changed over time. See 07Z0 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down LEPU MED.T.B. SP.GDR O.N.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of LEPU MED.T.B. SP.GDR O.N..

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €350.77 Million 1.37%
Total Liquid Assets €350.77 Million 1.37%

Asset Resilience Insights

  • Limited Liquidity: LEPU MED.T.B. SP.GDR O.N. maintains only 1.37% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

LEPU MED.T.B. SP.GDR O.N. Industry Peers by Asset Resilience Ratio

Compare LEPU MED.T.B. SP.GDR O.N.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen Mindray Bio-Medical Electronics Co Ltd Class A
SHE:300760
Medical Devices 0.64%
Demant A/S
CO:DEMANT
Medical Devices -2.59%
Double Medical Technology Inc
SHE:002901
Medical Devices 12.59%
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
Medical Devices 49.23%
Xiangyu Medical Co. Ltd. A
SHG:688626
Medical Devices 1.53%
Sino Medical Sciences Technology In
SHG:688108
Medical Devices 0.66%
Beijing Succeeder Technology Inc
SHG:688338
Medical Devices 28.27%
Eurobio Scientific SA
PA:ALERS
Medical Devices 10.52%

LEPU MED.T.B. SP.GDR O.N. Asset Resilience Ratio by Year (2022–2025)

LEPU MED.T.B. SP.GDR O.N. asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for LEPU MED.T.B. SP.GDR O.N..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.78% €203.31 Million
≈ $237.69 Million
€26.14 Billion
≈ $30.56 Billion
-0.34pp
2024-12-31 1.12% €274.86 Million
≈ $321.34 Million
€24.57 Billion
≈ $28.73 Billion
+0.02pp
2023-12-31 1.10% €275.20 Million
≈ $321.74 Million
€25.02 Billion
≈ $29.25 Billion
-0.03pp
2022-12-31 1.13% €277.21 Million
≈ $324.09 Million
€24.48 Billion
≈ $28.63 Billion
--
pp = percentage points

About LEPU MED.T.B. SP.GDR O.N.

F:07Z0 Germany Medical Devices
Market Cap
$174.62K
€149.36K EUR
Market Cap Rank
#31403 Global
#2790 in Germany
Share Price
€15.30
Change (1 day)
+0.00%
52-Week Range
€12.80 - €15.40
All Time High
€15.40
About

Lepu Medical Technology (Beijing) Co., Ltd., together with its subsidiaries, engages in the research, development, and manufacturing of cardiac interventional medical devices in China and internationally. The company operates through three segments: Medical Devices; Pharmaceuticals; and Medical Services and Health Management. It offers medical devices, including cardiovascular devices, in vitro d… Read more